nach oben

Immunologic Research

Erschienen in:

01.06.2015

Development of chimeric candidate vaccine against HPV18: a proof of concept

verfasst von: Mohammed Wahiduzzaman, Chandresh Sharma, Bindu Dey, Neerja Bhatla, Neeta Singh

Erschienen in: Immunologic Research | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Human papillomaviruses (HPVs) are prerequisite for the development of cervical cancer, with HPV16 and HPV18 being the most prevalent. Despite the fact that two prophylactic vaccines against HPVs are in the market, wide-scale application of the vaccine in developing countries is a major problem as far as cost of the vaccine and lack of therapeutic efficacy are concerned. Hence, the aim of our study was to develop HPV18 L1E7 chimeric virus-like particles (CVLPs) vaccine candidate possessing both, prophylactic and therapeutic potential against HPV18-associated cervical cancer. In this study, we have developed a potential candidate vaccine against HPV18 involving HPV18 L1E7 CVLPs, which was expressed in E. coli and assembled in vitro. These CVLPs were able to induce a neutralizing antibody response as well as a cell-mediated immune response in mice.

Nur mit Berechtigung zugänglich

Bernard HU, Burk BD, Chen Z, van Doorslaer K, Zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70–9.CrossRefPubMedCentralPubMed

Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl 3):1–10.CrossRef

Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol. 2004;4(1):46–54.CrossRefPubMed

Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med. 2009;361(3):271–8.CrossRefPubMed

Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immuno ther. 2012;8(3):390–7.CrossRef

Cid-Arregui A. Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol J. 2009;3:67–83.CrossRefPubMedCentralPubMed

Monie A, Tsen SW, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Expert Rev Vaccines. 2009;8(9):1221–35.CrossRefPubMedCentralPubMed

Hung CF, Ma B, Monie A, Tsen SW, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther. 2008;8(4):421–39.CrossRefPubMedCentralPubMed

Monie A, Hung CF, Wu TC. Preventive and therapeutic HPV vaccines. Curr Opin Investig Drugs. 2007;8(12):1038–50.PubMed

10.

Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 2007;98(10):1505–11.CrossRefPubMed

11.

Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res. 2002;89:213–28.CrossRefPubMed

12.

Eiben GL, Velders MP, Kast WM. The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. Adv Cancer Res. 2002;86:113–48.CrossRefPubMed

13.

Peng S, Trimble C, He L, Tsai YC, Lin CT, Boyd DA, et al. Characterization of HLAA2- restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther. 2006;13:67–77.CrossRefPubMedCentralPubMed

14.

Lin CT, Tsai YC, He L, Calizo R, Chou HH, Chang TC, et al. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci. 2006;13:481–8.CrossRefPubMed

15.

Jochmus I, Schafer K, Faath S, Muller M, Gissmann L. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res. 1999;30:269–74.CrossRefPubMed

16.

Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, et al. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer. 1999;81(6):881–8.CrossRefPubMed

17.

Schellenbacher C, Roden R, Kirnbauer R. Chimeric L1-L2 virus-like particles as potential broadspectrum human papillomavirus vaccines. J Virol. 2009;83(19):10085–95.CrossRefPubMedCentralPubMed

18.

Sharma C, Dey B, Wahiduzzaman M, Singh N. Human papillomavirus 16 L1–E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer. Vaccine. 2012;30:5417–24.CrossRefPubMed

19.

Bian T, Wang Y, Lu Z, Ye Z, Zhao L, Ren J, et al. Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice. Mol Cancer Ther. 2008;7(5):1329–35.CrossRefPubMed

20.

Roden RB, Hubbert NL, Kirnbauer R, Breitburd F, Lowy DR, Schiller JT. Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol. 1995;69(8):5147–51.PubMedCentralPubMed

21.

Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila). 2009;2(10):868–78.CrossRef

22.

Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccine. 2009;5(10):696–704.CrossRef

23.

Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14.CrossRefPubMed

24.

Yuan H, Estes PA, Chen Y, Newsome J, Olcese VA, Garcea RL, et al. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol. 2001;75:7848–53.CrossRefPubMedCentralPubMed

25.

Rollman E, Arnheim L, Collier B, Oberg D, Hall H, Klingstrom J, et al. HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses. Virology. 2004;322:182–9.CrossRefPubMed

26.

Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol. 1998;72:6151–4.PubMedCentralPubMed

27.

Chen XS, Casini G, Harrison SC, Garcea RL. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J Mol Biol. 2001;307:173–82.CrossRefPubMed

28.

Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small viruslike particles assembled from the L1 protein of human papillomavirus 16. Mol Cell. 2000;5(3):557–67.CrossRefPubMed

29.

Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757–65.CrossRefPubMed

30.

Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107:18–27.CrossRefPubMed

31.

Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol. 2007;178(8):5271–6.CrossRefPubMed

32.

Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181(6):1911–9.CrossRefPubMed

33.

Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst. 2003;95:1128–37.CrossRefPubMed

34.

Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol. 1996;70:3298–301.PubMedCentralPubMed

35.

Franconi R, Di Bonito P, Dibello F, Accardi L, Muller A, Cirilli A, et al. Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res. 2002;62:3654–8.PubMed

36.

Wilson VG, Rosas Acosta G. Molecular targets for papillomavirus therapy. Curr Drug Targets-Infect Disord. 2003;3:221–39.CrossRefPubMed

37.

Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol. 1995;154:5934–43.PubMed

38.

Castellanos MR, Hayes RL, Mitchell A, Maiman MD. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18. Gynecol Oncol. 2001;82:77–83.CrossRefPubMed

39.

Sharma C, Khan MA, Mohan T, Shrinet J, Latha N, Singh N. A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer. Immunol Res. 2014;58(1):132–8.CrossRefPubMed

40.

Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR, et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol. 2001;166:5346–55.CrossRefPubMed

41.

Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol. 2001;166:5917–24.CrossRefPubMed

42.

Dupuy C, Buzoni-Gatel D, Touze A, Le Cann P, Bout D, Coursaget P. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb Pathog. 1997;22(4):219–25.CrossRefPubMed

43.

Nakagawa M, Stites DP, Palefsky JM, Kneass Z, Moscicki AB. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses. Clin Diagn Lab Immunol. 1999;6(4):494–8.PubMedCentralPubMed

44.

Liu XS, Leerberg J, MacDonald K, Leggatt GR, Frazer IH. IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host. J Immunol. 2009;183(1):51–8.CrossRefPubMed

Titel: Development of chimeric candidate vaccine against HPV18: a proof of concept
verfasst von: Mohammed Wahiduzzaman
Chandresh Sharma
Bindu Dey
Neerja Bhatla
Neeta Singh
Publikationsdatum: 01.06.2015
Verlag: Springer US
Erschienen in: Immunologic Research / Ausgabe 2/2015
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-015-8650-4

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Development of chimeric candidate vaccine against HPV18: a proof of concept

Abstract

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Erratum to: History of narcolepsy at Stanford University

Elevated follicular helper T Cells and expression of IL-21 in thyroid tissues are involved in the pathogenesis of Graves’ disease

Profound blockade of T cell activation requires concomitant inhibition of different class I PI3K isoforms

Pretreatment with lipopolysaccharide attenuates diethylnitrosamine-caused liver injury in mice via TLR4-dependent induction of Kupffer cell M2 polarization

Decreased expression of microRNA-125a-3p upregulates interleukin-23 receptor in patients with Hashimoto’s thyroiditis

STAT4 genetic polymorphisms association with spontaneous clearance of hepatitis B virus infection

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update HNO